Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
company delivered fourth quarter of 2022 operating loss of $-40.428 millions
Published Mar 08 2023
CSIMarket Team / CSIMarket.com
Revenues remained unscathed to $0.00 millions from $4.05 millions in the same reporting season a year ago and sequentially from $0.00 millions.
For the fiscal span closing December 31 2022 Scholar Rock Holding Corp realized net deficit of $-39.255 million, larger than $-35.914 million a year ago.
Even more, the company pointed out also net loss of $-134.50 millions and for the financial period 2022, Revenues of $33.19 millions.
Biotechnology & Pharmaceuticals The company has decreased it's deficit per share to $-2.26 from $-3.59 in the prior fiscal year, while Revenues surged by 76.41 % from $18.82 millions a year ago.
Scholar Rock Holding Corp is expected to report next financial recent numbers on May 15, 2023.
Other SRRK's news
Scholar Rock Reports Strong Financial Results and Advances in Antimyostatin Pipeline for 2023
Scholar Rock Empowers New Hires with Inducement Equity Awards Amidst Company Expansion
Scholar Rock*s Resilience Shown Through Board Appointments and Financial Transformations
Scholar Rock Unveils Preclinical Data on the Potential Role of SRK-439 in Combatting Obesity
Scholar Rock Grants Inducement Equity Awards to New Employees
Scholar Rock: Pioneering Breakthrough Treatments for Devastating Diseases
Scholar Rock*s Inducement Grants and their Ripple Effect on Company Shares
Headline: Scholar Rock Holding Corp Faces Growing Operating Expenses in Fourth Quarter of 2023
Scholar Rock Holding Corp Shines with Surprising Growth, Signals Optimistic Future
Scholar Rock Holding Corp*s Financial Woes Deepen in First Quarter of 2023
Other SRRK's news
Scholar Rock Reports Strong Financial Results and Advances in Antimyostatin Pipeline for 2023
Scholar Rock Empowers New Hires with Inducement Equity Awards Amidst Company Expansion
Scholar Rock*s Resilience Shown Through Board Appointments and Financial Transformations
Scholar Rock Unveils Preclinical Data on the Potential Role of SRK-439 in Combatting Obesity
Scholar Rock Grants Inducement Equity Awards to New Employees
Scholar Rock: Pioneering Breakthrough Treatments for Devastating Diseases
Scholar Rock*s Inducement Grants and their Ripple Effect on Company Shares
Headline: Scholar Rock Holding Corp Faces Growing Operating Expenses in Fourth Quarter of 2023
Scholar Rock Holding Corp Shines with Surprising Growth, Signals Optimistic Future
Scholar Rock Holding Corp*s Financial Woes Deepen in First Quarter of 2023